Webdisclosure.com

Search

ADC THERAPEUTICS SA EQS-News: ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and IMFINZI(R) (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma

Directive transparence : information réglementée

13/02/2019 07:00